Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Burgeoning Clinical Trial Business in China
August 22, 2005
- 1st Qtr Business Results
August 22, 2005
- NEW PRODUCTS
August 22, 2005
- Associations Petition for Rapid Increase in Review Staff
August 22, 2005
- Olympus, Terumo to Develop New Medical Devices Based on Capital Alliance
August 22, 2005
- SELF-MEDICATION
August 22, 2005
- Retirees Drove Growth in Medical Expenditure in FY2004: Survey
August 22, 2005
- 1st Qtr Business Results
August 8, 2005
- Average Salary Hikes in 2005 Slightly Down from 2004: Survey
August 8, 2005
- Fujifilm Subsidiary to Launch Package Insert Design Software
August 8, 2005
- Doctors' Influence on Drug Selection Is Decreasing: Mr Baba
August 8, 2005
- BUSINESS NEWS IN BRIEF
August 8, 2005
- NEW PRODUCTS
August 8, 2005
- 4th Scientific Meeting of Japan Society of Generic Medicine
August 8, 2005
- Toyama Prefecture to Establish Council to Promote GE Drug Use
August 8, 2005
- Council Recommends Early NDA Submission for Avastin
August 8, 2005
- PGx Must Be Included in More Clinical Trials in Japan: Symposium
August 8, 2005
- Takeda's Measles + Rubella Vaccine Recommended for Approval
August 8, 2005
- R&D NEWS IN BRIEF
August 8, 2005
- Industry Challenges Chuikyo with New Proposals
August 8, 2005
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…